These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

132 related items for PubMed ID: 22217390

  • 1. Effects of a long-acting ophthalmic formulation of carteolol containing alginic acid on the corneal epithelial barrier function and water retentive effect.
    Tokuda N, Inoue J, Yamazaki I, Ueno S, Fujisawa S.
    J Ocul Pharmacol Ther; 2012 Apr; 28(2):123-8. PubMed ID: 22217390
    [Abstract] [Full Text] [Related]

  • 2. A new long acting ophthalmic formulation of carteolol containing alginic acid.
    Séchoy O, Tissié G, Sébastian C, Maurin F, Driot JY, Trinquand C.
    Int J Pharm; 2000 Oct 10; 207(1-2):109-16. PubMed ID: 11036236
    [Abstract] [Full Text] [Related]

  • 3. Comparison of carteolol plasmatic levels after repeated instillations of long-acting and regular formulations of carteolol 2% in glaucoma patients.
    Renard P, Kovalski JL, Cochereau I, Jaulerry S, Williamson W, Elena PP, Lablache Combier M, Allaire C, Siou-Mermet R.
    Graefes Arch Clin Exp Ophthalmol; 2005 Dec 10; 243(12):1221-7. PubMed ID: 16003515
    [Abstract] [Full Text] [Related]

  • 4. Ocular hypotensive efficacy and safety of once daily carteolol alginate.
    Demailly P, Allaire C, Trinquand C, Once-daily Carteolol Study Group.
    Br J Ophthalmol; 2001 Aug 10; 85(8):921-4. PubMed ID: 11466245
    [Abstract] [Full Text] [Related]

  • 5. [Ocular hypotensive effect of 1% carteolol long-acting eye drops--a double-masked, randomized phase III study in ocular hypertension or primary open-angle glaucoma patients comparing long-acting carteolol eye drops vs. current product].
    Yamamoto T, Carteolol Long-acting Formulation Study Group.
    Nippon Ganka Gakkai Zasshi; 2007 Jun 10; 111(6):463-72. PubMed ID: 17601060
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Pharmacokinetic and pharmacodynamic differences between ocular and nasal instillation of carteolol on intraocular pressure and heart rate in Japanese men with high CYP2D6 activity.
    Ishii Y, Nakamura K, Matsuki S, Uemura N, Muraguchi R, Nakagawa M, Nakano S, Nakatsuka K.
    J Clin Pharmacol; 2002 Sep 10; 42(9):1020-6. PubMed ID: 12211218
    [Abstract] [Full Text] [Related]

  • 8. Alginic acid effect on carteolol ocular pharmacokinetics in the pigmented rabbit.
    Tissié G, Sébastian C, Elena PP, Driot JY, Trinquand C.
    J Ocul Pharmacol Ther; 2002 Feb 10; 18(1):65-73. PubMed ID: 11858616
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. [Long-acting carteolol hydrochloride 2% ophthalmic solution phase IV study--investigation of the effectiveness, safety and plasma concentration].
    Kawase K, Yamamoto T, Muramatsu T, Ono J, Nakajima T, Matsuhisa A, Sugiura T, Migita M, Ishikawa Y.
    Nippon Ganka Gakkai Zasshi; 2010 Nov 10; 114(11):976-82. PubMed ID: 21141077
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Pharmacokinetics of topical beta-adrenergic antagonists in rabbit aqueous humor evaluated with the microdialysis method.
    Ohtori R, Sato H, Fukuda S, Ueda T, Koide R, Kanda Y, Kiuchi Y, Oguchi K.
    Exp Eye Res; 1998 Apr 10; 66(4):487-94. PubMed ID: 9593641
    [Abstract] [Full Text] [Related]

  • 13. Effect of topical beta-blockers on tissue blood flow in the human optic nerve head.
    Tamaki Y, Araie M, Tomita K, Nagahara M, Tomidokoro A.
    Curr Eye Res; 1997 Nov 10; 16(11):1102-10. PubMed ID: 9395769
    [Abstract] [Full Text] [Related]

  • 14. Enhancement in Corneal Permeability of Dissolved Carteolol by Its Combination with Magnesium Hydroxide Nanoparticles.
    Nagai N, Yamaoka S, Fukuoka Y, Ishii M, Otake H, Kanai K, Okamoto N, Shimomura Y.
    Int J Mol Sci; 2018 Jan 17; 19(1):. PubMed ID: 29342127
    [Abstract] [Full Text] [Related]

  • 15. [Effect of latanoprost on the barrier function of corneal epithelium].
    Ishibashi T, Mori K, Adachi W, Naruse S, Hino Y, Komuro A, Yokoi N, Kinoshita S.
    Nippon Ganka Gakkai Zasshi; 2001 May 17; 105(5):333-7. PubMed ID: 11406950
    [Abstract] [Full Text] [Related]

  • 16. Effects of topical adrenergic agents on tissue circulation in rabbit and human optic nerve head evaluated with laser speckle tissue circulation analyzer.
    Tamaki Y, Araie M, Tomita K, Tomidokoro A, Nagahara M.
    Surv Ophthalmol; 1997 Nov 17; 42 Suppl 1():S52-63. PubMed ID: 9603290
    [Abstract] [Full Text] [Related]

  • 17. Time course of changes in ocular aberrations after instillation of carteolol long-acting solution and timolol gel-forming solution.
    Hiraoka T, Daito M, Okamoto F, Kiuchi T, Oshika T.
    J Ocul Pharmacol Ther; 2011 Apr 17; 27(2):179-85. PubMed ID: 21314439
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Efficacy and safety of the fixed combinations of tafluprost/timolol and latanoprost/carteolol.
    Fuwa M, Shimazaki A, Mieda M, Yamashita N, Akaishi T, Taniguchi T, Kato M.
    Sci Rep; 2019 May 16; 9(1):7491. PubMed ID: 31097790
    [Abstract] [Full Text] [Related]

  • 20. Effect of topical carteolol on iridial circulation in pigmented rabbit eyes.
    Tomidokoro A, Tamaki Y, Araie M, Tomita K, Muta K.
    Jpn J Ophthalmol; 1998 May 16; 42(3):180-5. PubMed ID: 9690895
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.